Literature DB >> 3979021

Occurrence and antimicrobial susceptibility of gram-negative nonfermentative bacilli in cystic fibrosis patients.

J D Klinger, M J Thomassen.   

Abstract

Isolation of nonfermentative gram-negative bacilli (other than Pseudomonas aeruginosa) from respiratory tract cultures of cystic fibrosis (CF) patients has increased in recent years. Species recovered include Pseudomonas cepacia, P. maltophilia, P. fluorescens/putida, P. alcaligenes, P. pseudoalcaligenes, P. stutzeri, Acinetobacter spp., Achromobacter xylosoxidans, Flavobacterium spp., and CDC groups IVe and Ve. Although colonization with most of these organisms is sporadic, P. cepacia (and to a lesser extent, P. maltophilia) is usually isolated consistently, and can be associated with significant clinical deterioration. Occurrence of P. cepacia in CF respiratory tract cultures obtained close to the time of death rose nearly ten-fold from 1979 to 1982. Strains representing all nonfermentative gram-negative species encountered were assayed for susceptibility to 17 newer antimicrobial agents. Ceftazidime, n-formimidoyl thienamycin, and aztreonam were most active; cefsulodin, ceforanide, and ceftriaxone were not active against these isolates.

Entities:  

Mesh:

Year:  1985        PMID: 3979021     DOI: 10.1016/0732-8893(85)90025-2

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  32 in total

Review 1.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

2.  Molecular epidemiology of Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans in a cystic fibrosis center.

Authors:  H Vu-Thien; D Moissenet; M Valcin; C Dulot; G Tournier; A Garbarg-Chenon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-11       Impact factor: 3.267

3.  The Brief Case: Extragenitourinary Location of Oligella urethralis.

Authors:  Clémence Beauruelle; Hervé Le Bars; Simon Bocher; Didier Tandé; Geneviève Héry-Arnaud
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

4.  Pseudomonas infections in cystic fibrosis.

Authors:  R H George
Journal:  Arch Dis Child       Date:  1987-05       Impact factor: 3.791

5.  Superiority of molecular techniques for identification of gram-negative, oxidase-positive rods, including morphologically nontypical Pseudomonas aeruginosa, from patients with cystic fibrosis.

Authors:  Nele Wellinghausen; Juliane Köthe; Beate Wirths; Anja Sigge; Sven Poppert
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

Review 6.  Characteristics of Bordetella hinzii strains isolated from a cystic fibrosis patient over a 3-year period.

Authors:  G Funke; T Hess; A von Graevenitz; P Vandamme
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

7.  Infection by Ralstonia species in cystic fibrosis patients: identification of R. pickettii and R. mannitolilytica by polymerase chain reaction.

Authors:  Tom Coenye; Peter Vandamme; John J LiPuma
Journal:  Emerg Infect Dis       Date:  2002-07       Impact factor: 6.883

8.  Evaluation of colistin susceptibility in multidrug-resistant clinical isolates from cystic fibrosis, France.

Authors:  S Biswas; J-C Dubus; M Reynaud-Gaubert; N Stremler; J-M Rolain
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-05-30       Impact factor: 3.267

Review 9.  Cystic fibrosis. Infection and immunity to Pseudomonas.

Authors:  R U Sorensen; R L Waller; J D Klinger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

10.  Comparative evaluation of selective media for isolation of Pseudomonas cepacia from cystic fibrosis patients and environmental sources.

Authors:  L A Carson; O C Tablan; L B Cusick; W R Jarvis; M S Favero; L A Bland
Journal:  J Clin Microbiol       Date:  1988-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.